The objective of this randomized multicenter trial of irbesartan, a novel, non-peptide angiotensin antagonist, is to determine efficacy in reducing the rate of progression of renal disease and adverse clinical sequelae in hypertensive patients with diabetic nephropathy due to Type II diabetes. The lab was used for oligonucleotide synthesis.
Showing the most recent 10 out of 470 publications